Collaboration is an important aspect of Apexigen's business model. At present, seven corporate collaborations are in place, representing both product development collaborations and antibody technology collaborations. Through the building of successful collaborations, Apexigen is able to develop a broad base of antibody products and promote wider use of its antibody technology platform. Additional information is available at www.apexigen.com.
Contact: Mark NevinsVice President, Business Development(650) 931-6236 ext 502 email@example.com
SOURCE Apexigen, Inc.